S-1/A: 180 Life Sciences Corp. Seeks to Raise Capital Through Share and Warrant Offering Amidst Nasdaq Compliance Concerns

180 Life Sciences Corp. is offering up to 3,296,703 shares of common stock along with warrants to raise capital, while also addressing Nasdaq listing compliance and exploring strategic alternatives.

Summary

• 180 Life Sciences Corp. has filed an amendment to its Form S-1 registration statement to offer up to 3,296,703 shares of common stock, pre-funded warrants, and common warrants.
• The company is offering common warrants to purchase up to 3,296,703 shares of common stock, with an assumed exercise price of $1.82 per share and a five-year term.
• Pre-funded warrants are also being offered to purchasers who would beneficially own more than 4.99% (or 9.99%) of the company's outstanding common stock after the offering, with an exercise price of $0.0001 per share.
• The offering will terminate no later than November 14, 2024, but the shares underlying the pre-funded warrants and common warrants will be offered on a continuous basis.
• The company is exploring strategic alternatives, including a potential acquisition, merger, or sale of assets, to maximize stockholder value.
• The company's current cash balance is expected to fund operations only until approximately November 2024.
• The company is not in compliance with Nasdaq's continued listing standards and may face delisting.
• The company intends to use the net proceeds from the offering for research and development expenses, transaction costs for a strategic transaction, legal expenses, and working capital.
• The company has agreed to pay the Placement Agent a cash placement commission equal to 7% of the aggregate proceeds from this offering.

Sentiment

Score: 4

Explanation: The document presents a mixed sentiment. While the company is actively pursuing strategic alternatives and has achieved some positive outcomes in litigation, it faces significant financial challenges, including a limited cash runway and non-compliance with Nasdaq listing standards. The need for additional funding and the potential for delisting contribute to a negative outlook.

Positives

• The company is actively exploring strategic alternatives to maximize value for its stockholders.
• The company has settled a lawsuit with Tyche Capital LLC, resulting in a gain of $156,891 during the three months ended June 30, 2024.
• The company has entered into a settlement with Freedom Specialty Insurance Company, pursuant to which Freedom has agreed to pay $125,000 to the Company.
• The company has been granted additional time until September 30, 2024, to regain compliance with Nasdaq's continued listing rules.

Negatives

• The company's current cash balance is only expected to be sufficient to fund its planned business operations until approximately November 2024.
• The company is not in compliance with Nasdaq's continued listing standards and may face delisting.
• The company has a working capital deficit of $1,668,637 as of June 30, 2024.
• The company has significant accounts payable and may not have sufficient funds to pay them.
• The company may not receive any further amount under its pre-merger directors and officers insurance policy in connection with certain litigation matters.

Risks

• The company's current cash balance is only expected to be sufficient to fund its planned business operations until approximately November 2024.
• The company may not be able to obtain additional financing on terms favorable to it, if at all.
• The company is not in compliance with Nasdaq's continued listing standards and may face delisting.
• The company's future product candidates may not receive regulatory approval or be successfully commercialized.
• The company may be subject to litigation and damages for its failure to pay amounts due to the University of Oxford.
• The market price of the company's common stock has been extremely volatile and may continue to be volatile due to numerous circumstances beyond its control.
• The company may amend the terms of outstanding Common Warrants to purchase up to an aggregate of 954,118 shares of our Common Stock which currently have an exercise price of $3.23 per share, to reduce the exercise price of such warrants to equal the exercise price of the Common Warrants sold in this offering, and to extend the term during which those warrants could remain exercisable to the term of the Common Warrants sold in this offering, respectively.

Future Outlook

The company is evaluating all options to monetize its existing assets, in addition to exploring other strategic alternatives to maximize value for its stockholders. The company's current cash balance is only expected to be sufficient to fund its planned business operations until approximately November 2024.

Management Comments

• The Company is currently evaluating all options to monetize its existing assets, in addition to exploring other strategic alternatives to maximize value for its stockholders.
• To date, the Board of Directors has had discussions with several parties regarding potential transactions, but has not made a final determination regarding which type of transaction or which transaction to pursue as of the date of this prospectus.

Industry Context

The biotechnology industry is highly competitive, and 180 Life Sciences faces risks from companies with greater resources and experience. The company's success depends on the regulatory approval and commercialization of its product candidates.

Comparison to Industry Standards

• It is difficult to compare 180 Life Sciences to industry standards due to its unique focus on chronic pain, inflammation, and fibrosis using innovative research and combination therapy.
• Many comparable companies in the biotechnology industry, such as Amgen, Biogen, and Gilead Sciences, have significantly larger market capitalizations and established revenue streams.
• Smaller, clinical-stage biotechnology companies often face challenges in securing funding and achieving regulatory approval, which are common risks across the industry.

Management Changes

Legal Proceedings

• The Company is involved in a Declaratory Relief Action with AmTrust International Underwriters DAC regarding insurance coverage obligations.
• The Company, Freedom and Amtrust held a mediation conference on August 21, 2024, during which, the Company agreed to the terms of a settlement with Freedom, pursuant to which Freedom has agreed to pay $125,000 to the Company.
• The Company dismissed its lawsuit against Tyche in the Supreme Court of New York in the County of New York with prejudice.

Stakeholder Impact

• Shareholders face potential dilution from the offering and the exercise of warrants.
• Shareholders face the risk of delisting from Nasdaq, which could negatively impact the stock price and liquidity.
• Employees may be affected by potential strategic alternatives, including acquisitions or mergers.
• Creditors may be impacted by the company's ability to meet its financial obligations.

Next Steps

• The company intends to seek stockholder approval for the issuance of shares of common stock upon exercise of the Common Warrants.
• The company is continuing to work towards completing the necessary transactions in an effort to achieve compliance with the Equity Rule.
• The Company is currently seeking out qualified independent directors to serve on the Company's audit committee and expects to regain compliance with Listing Rule 5605(c)(2) in the near future.

Key Dates

Keywords

common stock, warrants, offering, Nasdaq, compliance, strategic alternatives, capital, pre-funded warrants, listing, 180 Life Sciences